In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii

被引:0
作者
Xiaomeng Dong
Fengzhe Chen
Yajun Zhang
Haihong Liu
Yongjuan Liu
Lixian Ma
机构
[1] Qilu Hospital,Department of Infectious Disease
[2] Shandong University,undefined
来源
The Journal of Antibiotics | 2014年 / 67卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to investigate the in vitro activities of rifampin, colistin, sulbactam and tigecycline alone and in combination against extensively drug-resistant Acinetobacter baumannii (XDR-Ab). Twenty-five XDR-Ab strains were isolated from patients. Broth microdilution assay was used to determine the minimum inhibitory concentration (MIC) for rifampin, colistin, sulbactam and tigecycline against XDR-Ab strains. The checkerboard microdilution method was used to determine the in vitro activities of potential therapeutic combinations of these four antimicrobial agents. Accordingly, the fractional inhibitory concentration (FIC) and FIC index (FICI) were calculated for each of the combinations. According to our results, when tested as single drugs, rifampin, colistin or tigecycline had good bacteriostatic activity against XDR-Ab, whereas sulbactam was not as active against XDR-Ab isolates. On the other hand, when tested in combination, the combinations of colistin/rifampin, rifampin/sulbactam, rifampin/tigecycline and sulbactam/tigecycline showed good in vitro activities against XDR-Ab isolates. More importantly, these combination regimens could exert addictive or partially synergistic effects at the sub-MIC levels against XDR-Ab strains. Compared with single drugs, most of the combinations of these antimicrobial agents could exert partially synergistic and/or addictive effects, which might provide a better alternative when treating XDR-Ab infections.
引用
收藏
页码:677 / 680
页数:3
相关论文
共 32 条
[1]  
Playford EG(2007)Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and consequences J. Hosp. Infect. 65 204-211
[2]  
Craig JC(2012)Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin. Microbiol. Infect. 18 268-281
[3]  
Iredell JR(2000)Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii J. Clin. Microbiol. 38 4086-4095
[4]  
Magiorakos A-P(2006)Functional, biophysical, and structural bases for antibacterial activity of tigecycline Antimicrob. Agents. Chemother. 50 2156-2166
[5]  
Corbella X(2014)Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase J. Antimicrob. Chemother. 69 72-76
[6]  
Olson MW(2012)Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian. J. Med. Microbiol. 30 448-452
[7]  
Chen Q(2013) activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii Int. J. Antimicrob. Agents. 41 400-401
[8]  
Simsek F(2011)Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens Yonsei. Med. J. 52 879-891
[9]  
Ji J(2007)An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii Nat. Rev. Microbiol. 5 939-951
[10]  
Lee K(2008)Acinetobacter baumannii: emergence of a successful pathogen Clin. Microbiol. Rev. 21 538-582